Introduction

Europe’s biotechnology sector has evolved into a global powerhouse, driving breakthroughs in mRNA vaccines, gene therapies, and antibody treatments. European biotech companies were instrumental in the COVID-19 pandemic, notably with BioNTech’s mRNA vaccine, and continue to advance therapies in oncology, rare diseases, and metabolic disorders. The region now hosts multiple biotech firms with valuations in the billions, reflecting a thriving ecosystem backed by robust scientific research, growing investments, and strategic partnerships. This report provides a comprehensive analysis of the top 25 European biotech companies, detailing their market size, focus areas, innovations, and key collaborations. It also examines broader industry trends, regulatory dynamics, and funding conditions shaping the future of European biotech. The report follows a structured, data-driven approach, similar to strategic analyses by McKinsey and BCG, offering clear insights into Europe’s biotech trajectory.

‍

Top 25 European Biotech Companies

Europe is home to a diverse range of biotech companies specializing in therapeutic areas such as oncology, immunology, metabolic disorders, and infectious diseases. Below is an in-depth look at 25 leading European biotech firms, including their market capitalization, key therapeutic products, pipeline developments, and industry impact. Market capitalizations are approximate and subject to change, while revenue and funding figures reflect the latest available data.

BioNTech (Germany)

BioNTech became a global name with the development of the first approved mRNA COVID-19 vaccine, Comirnaty, in collaboration with Pfizer. The success of this vaccine propelled its revenue to €17.3 billion in 2022, while its market capitalization currently stands at approximately $28–30 billion. Beyond COVID-19, BioNTech is expanding into oncology, aiming for at least ten oncology product approvals by 2030. Its pipeline includes personalized mRNA cancer vaccines, cell-based immunotherapies, and next-generation checkpoint inhibitors. The company has made significant strides in artificial intelligence for drug discovery, including the acquisition of AI-driven biotech firm InstaDeep in 2023 to enhance machine learning applications in R&D. Key partnerships include Pfizer for vaccines, Genentech for personalized cancer immunotherapies, and multiple academic institutions worldwide. With €17.7 billion in cash reserves, BioNTech has ample resources to continue its aggressive expansion into oncology and infectious diseases.

‍

Genmab (Denmark)

Genmab is a leader in antibody-based therapeutics for oncology and autoimmune diseases, with a current market capitalization of approximately $25 billion. The company’s flagship product, Darzalex (daratumumab), a monoclonal antibody for multiple myeloma marketed by Johnson & Johnson’s Janssen, has generated billions in global sales. Other key products include Arzerra (ofatumumab) for leukemia and Tivdak (tisotumab vedotin), an antibody-drug conjugate for cervical cancer co-developed with Seagen. In 2023, Genmab achieved another milestone with the FDA approval of epcoritamab (Epkinly), the first bispecific T-cell engager for certain lymphomas, in partnership with AbbVie. Genmab's proprietary antibody engineering platforms have yielded multiple successful therapies, reinforcing Europe's strength in biologics. The company maintains strategic collaborations with J&J, GSK, Seagen, and AbbVie, leveraging these partnerships to expand its global footprint while generating substantial royalty streams from licensed therapies.

‍

Novo Nordisk (Denmark)

Novo Nordisk is the most valuable company in Europe, with a market capitalization of approximately $540 billion as of early 2024. Specializing in diabetes, obesity, and metabolic diseases, the company has transformed treatment paradigms with its GLP-1 receptor agonists, including Ozempic and Wegovy (semaglutide). Demand for these therapies has skyrocketed, driving Novo Nordisk’s annual revenue to $33.7 billion in 2023. Semaglutide has been a game-changer in obesity management, with clinical trials demonstrating unprecedented weight loss benefits, positioning it as a disruptive therapy in metabolic health. Novo Nordisk has consistently invested in RNAi technology, gene editing, and peptide therapeutics, notably acquiring Dicerna Pharmaceuticals for $3.3 billion to enhance its RNAi capabilities and Inversago Pharma for $1 billion to expand its obesity pipeline. The company actively collaborates with research institutes and smaller biotech firms to drive innovation. With obesity and metabolic diseases projected to be multi-billion-dollar markets, Novo Nordisk remains at the forefront of biopharmaceutical innovation, further solidifying Europe's leadership in healthcare biotech.

‍

‍

Argenx (Belgium/Netherlands)

Argenx has emerged as one of Europe’s leading biotech companies, with a market capitalization of approximately $39 billion. The company specializes in antibody-based therapies, particularly for autoimmune diseases and cancer. Its flagship drug, efgartigimod (Vyvgart), is a first-in-class antibody fragment approved by the FDA in late 2021 for generalized myasthenia gravis. The treatment demonstrated significant improvements in patient mobility in Phase 3 trials, positioning it as a transformative therapy in neuromuscular disorders.

Argenx is rapidly expanding efgartigimod’s applications to additional autoimmune conditions, including immune thrombocytopenia and chronic inflammatory demyelinating polyneuropathy. The company’s innovative approach leverages its proprietary “Immunobody” platform, which capitalizes on llama-derived antibody fragments known for their high specificity and stability. This unique methodology has enabled the development of highly targeted therapies with fewer side effects compared to conventional antibody treatments.

Strategically, argenx has formed key collaborations to accelerate commercialization. Early alliances with Leo Pharma in dermatology and regional partnerships for Vyvgart distribution have supported its global footprint. The company is dual-listed on Euronext Brussels and Nasdaq, reflecting its international investment appeal. With robust cash reserves from its successful drug launch, argenx is positioned as a leader in autoimmune therapy and continues to invest heavily in research and development to expand its innovative pipeline.

‍

Lonza (Switzerland)

Lonza plays a critical role in the biotechnology sector as a leading contract development and manufacturing organization (CDMO) rather than a traditional drug developer. With a market capitalization of approximately $46 billion, the company provides manufacturing and bioprocessing solutions for biologics, cell and gene therapies, and vaccines. Lonza was instrumental in scaling production for Moderna’s mRNA COVID-19 vaccine, underscoring its role in supporting global healthcare innovation.

The company has invested heavily in next-generation manufacturing capabilities, including continuous bioprocessing and viral vector production, positioning itself as a leader in the cell and gene therapy sector. Lonza has expanded its footprint through strategic acquisitions, such as the 2017 purchase of Capsugel, which enhanced its drug delivery technology portfolio.

Lonza operates through long-term supply agreements with top biotech and pharmaceutical companies, enabling it to maintain a stable revenue stream. Its global network of facilities, spanning Europe, North America, and Asia, ensures seamless manufacturing and regulatory compliance. As the demand for biologics and cell therapies continues to grow, Lonza remains a cornerstone of Europe’s biotech ecosystem, providing the infrastructure necessary to bring scientific breakthroughs to market.

‍

UCB (Belgium)

UCB, valued at approximately $36 billion, is a leading biotech company focused on neurology and immunology. The company’s flagship products include Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn’s disease, Vimpat (lacosamide) for epilepsy, and Neupro (rotigotine patch) for Parkinson’s disease. UCB’s strong neurology franchise, particularly in epilepsy treatments, has driven consistent revenue growth and reinforced its leadership in central nervous system disorders.

The company continues to expand its immunology and neurology pipelines with promising candidates such as bimekizumab, a novel IL-17 inhibitor for psoriasis and psoriatic arthritis, which received European regulatory approval in 2022. Another key asset is zilucoplan, a complement inhibitor acquired through the $2.1 billion purchase of Ra Pharma, which is being developed for myasthenia gravis.

UCB has strengthened its portfolio through strategic acquisitions, including the $1.9 billion acquisition of Zogenix to bolster its rare disease pipeline. The company has also partnered with Amgen to co-develop Evenity (romosozumab), a therapy for osteoporosis that is now marketed in Europe. With a focus on advancing biologics and small molecules for complex diseases, UCB continues to scale its presence in the global biopharmaceutical market.

‍

Evotec (Germany)

Evotec is a hybrid biotech company with a market capitalization of approximately €7–8 billion, offering both contract research services and an in-house drug discovery pipeline. The company collaborates with leading pharmaceutical firms on early-stage R&D while simultaneously developing its own therapies. With expertise spanning neuroscience, metabolic diseases, oncology, and infectious diseases, Evotec employs over 3,000 scientists worldwide.

Evotec has pioneered an open innovation model, building disease-specific research portfolios in collaboration with global partners. This strategy allows the company to share development risks and rewards while leveraging its high-throughput screening, medicinal chemistry, and AI-driven discovery capabilities. Notably, Evotec has expanded into gene therapy through a strategic partnership with Takeda, reflecting its commitment to cutting-edge biotechnologies.

Despite volatility in public markets, Evotec successfully launched a Nasdaq IPO in 2021, raising €376 million to fuel its expansion. The company remains at the center of Europe’s biotech ecosystem, actively contributing to initiatives such as the Alliance for Therapies in Infectious Diseases. Its broad collaborative network, diversified pipeline, and unique business model make Evotec a critical player in European biotech, bridging the gap between academic research and commercial drug development.

‍

Ascendis Pharma (Denmark)

Ascendis Pharma, with a market capitalization of approximately $8 billion, is a leading biotech company specializing in rare endocrine disorders and oncology. The company’s proprietary TransCon technology is a prodrug platform that extends the release of therapeutic molecules, improving patient compliance and enhancing treatment outcomes. This innovation allows for more convenient dosing schedules compared to traditional therapies.

The company’s flagship product, Skytrofa (lonapegsomatropin), was approved by the FDA in 2021 for pediatric growth hormone deficiency. It represents a major advancement in hormone therapy, enabling once-weekly dosing instead of daily injections. Skytrofa's approval has validated the TransCon technology, and Ascendis is now applying this platform to other indications. The pipeline includes TransCon PTH, currently in late-stage trials for hypoparathyroidism, and TransCon IL-2, an immuno-oncology candidate designed to enhance anti-tumor immunity.

Unlike many biotech companies that rely on partnerships, Ascendis retains full ownership of its therapies, allowing it to maintain greater financial and strategic control. However, the company has attracted interest from potential collaborators due to the platform nature of its TransCon technology. With Skytrofa generating commercial revenue and additional therapies approaching approval, Ascendis is poised for significant growth, exemplifying how European biotechs can thrive by targeting high-impact, niche medical needs.

‍

Oxford Nanopore Technologies (UK)

Oxford Nanopore Technologies, valued at approximately £5.3 billion (~€6.3 billion), is a leader in DNA/RNA sequencing technology. Unlike traditional short-read sequencing methods, Oxford Nanopore’s platform allows for real-time, long-read sequencing, which enables superior genomic analysis, including structural variations and epigenetic modifications.

The company’s portable sequencing devices, MinION and PromethION, have revolutionized DNA sequencing by making it accessible, cost-effective, and adaptable for field use. These innovations have been crucial in real-time pathogen surveillance, including tracking Ebola and COVID-19 variants globally. In 2020, Oxford Nanopore introduced a portable COVID-19 and flu diagnostic, reinforcing its position at the forefront of applied genomics.

In October 2021, the company successfully raised over €400 million in its London Stock Exchange IPO, marking one of the largest UK biotech listings. Oxford Nanopore has established strong partnerships with public health agencies, academic research centers, and pharmaceutical companies, further embedding its technology in both research and clinical applications. While not a therapeutic developer, the company plays a vital role in personalized medicine and genomics, making it a key enabler of biotech innovation in Europe.

‍

‍

CureVac (Germany)

CureVac, a pioneer in mRNA therapeutics, had a peak market capitalization of $7 billion in 2021 but has since declined following setbacks in its COVID-19 vaccine program. Founded in 2000, CureVac was one of the first companies to explore the potential of mRNA-based treatments, contributing to the foundational knowledge that now underpins the global mRNA revolution.

During the COVID-19 pandemic, CureVac secured €80 million in EU funding and €300 million from the German government to develop an mRNA vaccine. It also formed a €1 billion partnership with GSK in 2020 to co-develop next-generation mRNA vaccines. However, its initial COVID-19 vaccine candidate demonstrated lower-than-expected efficacy and was withdrawn from EMA review in 2021, ceding market leadership to BioNTech and Moderna.

Despite this setback, CureVac remains a key player in mRNA technology, now focusing on second-generation mRNA vaccines and cancer immunotherapies. With continued backing from the German government and strategic partnerships, the company is working to improve mRNA stability and efficacy, aiming to regain its position as a leader in mRNA-based medicine.

‍

CRISPR Therapeutics (Switzerland)

CRISPR Therapeutics, with a market capitalization of approximately $5–6 billion, is at the forefront of gene editing therapies using CRISPR/Cas9 technology. Co-founded by Nobel laureate Dr. Emmanuelle Charpentier, the company has established itself as a leader in developing curative gene therapies for genetic disorders.

Its lead program, exa-cel (exagamglogene autotemcel), is a CRISPR-based cell therapy developed in partnership with Vertex Pharmaceuticals for sickle cell disease and beta thalassemia. Clinical trials have demonstrated the potential for functional cures, with many treated patients becoming transfusion-independent. As of late 2023, exa-cel is under regulatory review and is expected to be the first CRISPR gene therapy to receive global approval.

CRISPR Therapeutics is also advancing allogeneic (off-the-shelf) CAR-T cell therapies for cancer, including its lead oncology candidate, CTX110, which showed promising early results in treating B-cell lymphoma. Other pipeline programs include a gene-edited diabetes cell therapy developed in collaboration with ViaCyte. The company has established strategic alliances with Vertex and other biotech firms, leveraging collaborations to accelerate development while maintaining control over key assets. If approved, exa-cel would mark a turning point in the gene therapy landscape and solidify Europe’s position in genetic medicine innovation.

‍

Galapagos (Belgium)

Galapagos, valued at $3–4 billion, focuses on small-molecule and cell therapies for inflammation, fibrosis, and kidney disease. Its most notable product, Jyseleca (filgotinib), an oral JAK inhibitor for rheumatoid arthritis, was developed with Gilead but faced regulatory hurdles. The FDA rejected its application in 2020 due to safety concerns, though the drug was successfully approved in Europe and Japan.

A major strategic shift occurred in 2022 when Galapagos pivoted to cell therapy, acquiring CellPoint and AboundBio to establish a presence in CAR-T immunotherapies. This marked a significant transition from its earlier focus on small molecules. Despite setbacks in its fibrosis pipeline—most notably the discontinuation of ziritaxestat in Phase 3—Galapagos remains a key European biotech player with a diversified pipeline and significant financial backing from Gilead, which invested ~$5 billion in 2019. The company is now focused on executing its new cell therapy strategy, aiming to establish a foothold in oncology and autoimmune disorders.

‍

Idorsia (Switzerland)

Idorsia, with a market capitalization of CHF 2.9 billion (€2.7 billion), was established as a spin-off from Actelion in 2017 following Actelion’s €28 billion acquisition by Johnson & Johnson. With a strong pipeline inherited from Actelion’s research division, Idorsia has quickly built a promising portfolio of neurology, cardiovascular, and rare disease therapies.

Its lead product, daridorexant (Quviviq), is a dual orexin receptor antagonist for insomnia that gained FDA and EMA approval in 2022. Clinical trials demonstrated improvements in both sleep onset and maintenance, validating Idorsia’s focus on central nervous system disorders. Other key pipeline candidates include lucerastat for Fabry disease and aprocitentan for resistant hypertension, the latter developed in partnership with J&J and approved by the FDA in early 2023. While Idorsia has a deep pipeline, it faces financial challenges, needing to scale revenue to sustain its expansive R&D efforts. The company exemplifies how European biotech can thrive post-acquisition, carrying forward innovative drug development even after big pharma buyouts.

‍

Valneva (France)

Valneva, valued at approximately €2.4 billion (~$2.7 billion), specializes in vaccine development for infectious diseases, with a focus on neglected conditions that larger pharmaceutical companies often overlook. The company made headlines in 2021 with its inactivated whole-virus COVID-19 vaccine, a unique alternative to mRNA-based vaccines. In Phase 3 trials, it demonstrated robust immune response with fewer side effects compared to AstraZeneca’s vaccine, leading to regulatory approvals in the UK and the EU in 2022. However, demand was limited as mRNA vaccines dominated global immunization campaigns.

Beyond COVID-19, Valneva has a promising pipeline, including VLA1553, a chikungunya vaccine candidate that achieved successful Phase 3 results in 2021 and is poised to be the first-ever vaccine for this mosquito-borne disease. The company is also co-developing VLA15, a Lyme disease vaccine, with Pfizer, now in Phase 3 trials, marking a potential breakthrough in preventing Lyme infections. Additionally, Valneva is developing vaccines for Zika virus and Clostridioides difficile, reinforcing its commitment to addressing high-burden infectious diseases.

Valneva’s strategic approach includes leveraging well-established vaccine platforms, such as whole-pathogen inactivation, to provide broader antigenic coverage. Despite facing challenges, including the UK government’s abrupt cancellation of a major COVID vaccine supply contract, the company has successfully pivoted, securing EU support and expanding its vaccine portfolio. Its partnership with Pfizer on Lyme disease underscores its growing influence in vaccine innovation, proving that European biotech firms can still drive progress in a field traditionally dominated by large pharmaceutical companies.

‍

‍

Prothena (Ireland)

Prothena, with a market capitalization of approximately €1.8 billion ($2.0 billion), is focused on protein misfolding disorders, developing antibody therapies for neurodegenerative and rare diseases characterized by toxic protein aggregates. Its most advanced program, prasinezumab, is a monoclonal antibody targeting alpha-synuclein, a key protein implicated in Parkinson’s disease. This therapy, developed in partnership with Roche, is currently in Phase 2 trials and represents one of the first attempts at passive immunotherapy for Parkinson’s, aiming to clear neurotoxic protein buildup in affected neurons.

Prothena is also advancing birtamimab, an antibody therapy targeting AL amyloidosis, and tafamidis-resistant ATTR amyloidosis treatments. The company is engaged in multiple collaborations, including with Bristol Myers Squibb for an Alzheimer’s tau-targeting program and Novo Nordisk, which acquired rights to Prothena’s ATTR amyloidosis antibody in 2023.

The company specializes in antibody therapies targeting misfolded proteins, a highly complex area of neuroscience. If successful, its approach could deliver the first disease-modifying treatment for Parkinson’s. As big pharmaceutical firms continue investing in neuroscience breakthroughs, Prothena stands out as a key European player in the race to develop innovative therapies for historically intractable diseases.

‍

MorphoSys (Germany)

MorphoSys, one of Europe’s longest-standing biotech firms, has a market capitalization of approximately €1.2 billion ($1.4 billion) after a sharp decline in recent years. Founded in 1992, MorphoSys pioneered a proprietary antibody library platform, which has led to multiple successful therapies through partnerships with major pharmaceutical companies.

The company’s key product, Tremfya (guselkumab), was discovered by MorphoSys and is marketed by Janssen for psoriasis, generating significant royalty revenue. MorphoSys also co-developed Monjuvi (tafasitamab), an antibody therapy for relapsed lymphoma, approved by the FDA in 2020 in collaboration with Incyte.

In a bold strategic move to shift from a technology licensor to a fully integrated biotech company, MorphoSys acquired Constellation Pharmaceuticals for $1.7 billion in 2021, gaining access to pelabresib, a BET inhibitor in Phase 3 trials for myelofibrosis. However, the acquisition was met with investor skepticism due to its high cost, leading to a 66% decline in MorphoSys’ stock value in 2021. The company’s future largely hinges on pelabresib’s success in myelofibrosis and the continued performance of its antibody pipeline. If successful, MorphoSys could reestablish itself as a leader in oncology and autoimmune therapies.

‍

Immunocore (UK)

Immunocore, valued at approximately €1.2 billion ($1.4 billion), is a trailblazer in T-cell receptor (TCR) therapies for cancer and infectious diseases. The company’s ImmTAX platform re-engineers TCRs to redirect T-cells to attack tumors or infected cells, offering a soluble alternative to CAR-T therapy.

The company’s breakthrough product, tebentafusp (Kimmtrak), became the first-ever FDA-approved TCR therapy in early 2022 for metastatic uveal melanoma, a rare and deadly form of eye cancer. The therapy significantly improved survival rates, marking a major milestone in immunotherapy and demonstrating the potential of TCR-based treatments.

Immunocore is also advancing TCR therapies for HIV and hepatitis B, supported by a partnership with the Bill & Melinda Gates Foundation. The company’s innovations stem from a lineage similar to CAR-T and checkpoint inhibitors, targeting intracellular tumor antigens that traditional monoclonal antibodies cannot recognize. Immunocore’s 2021 Nasdaq IPO, which raised $260 million, bolstered its financial position to accelerate its oncology and infectious disease programs. With a strong foundation in TCR-based immunotherapy, Immunocore exemplifies Europe’s strength in pioneering next-generation cancer treatments.

‍

uniQure (Netherlands)

UniQure, with a market capitalization of approximately €1.1 billion ($1.3 billion), is a leader in gene therapy, focusing on rare genetic diseases. The company was behind Glybera, the first-ever gene therapy approved in Europe in 2012 for familial lipoprotein lipase deficiency. While a scientific breakthrough, Glybera’s commercial viability was limited, leading to its withdrawal in 2017.

UniQure has since shifted its focus to more commercially viable gene therapies, with its most notable program being etranacogene dezaparvovec (Hemgenix), a gene therapy for hemophilia B, developed in partnership with CSL Behring. Following positive Phase 3 results, FDA approval was granted in 2022, making it the first gene therapy for hemophilia B. UniQure also has pipeline programs for Huntington’s disease (Phase 1/2 trials) and refractory temporal lobe epilepsy (preclinical studies).

UniQure’s expertise in AAV vector design and manufacturing has positioned it as a key player in gene therapy. Its strategic decision to partner with CSL Behring for the commercialization of Hemgenix ensures a strong revenue stream while allowing it to focus on expanding its gene therapy pipeline. As gene therapy continues to evolve, uniQure remains one of Europe’s most influential players in the space.

‍

Horizon Therapeutics (Ireland)

Horizon Therapeutics, valued at approximately $22–23 billion prior to its acquisition, specialized in rare autoimmune and inflammatory diseases. Its flagship product, Tepezza (teprotumumab), is the first and only FDA-approved treatment for Thyroid Eye Disease, a condition that previously had limited options beyond steroids or surgery. Approved in 2020, Tepezza significantly improved symptoms such as eye bulging and double vision, setting a new standard for treatment.

Other major products include Krystexxa (pegloticase) for refractory gout and Uplizna (inebilizumab) for neuromyelitis optica spectrum disorder. Horizon grew rapidly by acquiring and developing orphan disease therapies, expanding its rare disease portfolio to over 10 marketed medicines. Its ability to drive innovation in niche therapeutic areas made it one of the fastest-growing biotech firms before its acquisition.

In late 2022, Horizon announced its $27.8 billion acquisition by Amgen, one of the largest biotech deals in history. The acquisition, completed in 2023, underscores the growing trend of big pharma targeting biotech firms with successful commercial portfolios. While Horizon was headquartered in Dublin for tax purposes, most of its operations were based in the United States. Its trajectory exemplifies how European biotech firms can scale to global success before being integrated into larger pharmaceutical companies. With Amgen’s global reach, Horizon’s therapies will now expand to a broader patient base worldwide.

‍

‍

Grifols (Spain)

Grifols, with a market capitalization of approximately $6–7 billion, is a global leader in plasma-derived biopharmaceuticals, producing essential medicines for immune deficiencies, bleeding disorders, and neurological diseases. The company specializes in plasma fractionation and protein purification, a critical but often overlooked area of biotech innovation.

Its key products include immunoglobulins (IVIG) for immune deficiencies, albumin for shock and liver disease, clotting factors for hemophilia, and hyperimmune globulins for conditions such as rabies and tetanus. Grifols is one of the world’s largest suppliers of plasma-derived therapies, competing with CSL (Australia) and Takeda (through Baxalta).

A family-founded company, Grifols expanded aggressively through international acquisitions, most notably acquiring Talecris (USA) for $3.4 billion in 2011 and Biotest (Germany) in 2021, strengthening its global plasma collection and product portfolio. However, rapid expansion also resulted in high debt levels, leading to fluctuations in its market valuation.

Grifols operates independently but partners with health authorities and governments on plasma donation drives and federal agencies for antibody therapies, including convalescent plasma for COVID-19. Despite regulatory scrutiny on plasma supply chains, Grifols remains a cornerstone of European biotech, ensuring the global supply of life-saving plasma-derived medicines.

‍

Ipsen (France)

Ipsen, valued at approximately €9–10 billion (~$10 billion), is a specialty biopharmaceutical company focused on oncology, neuroscience, and rare diseases. Its leading products include Somatuline (lanreotide), a biologic treatment for neuroendocrine tumors and acromegaly, Dysport (botulinum toxin) for neurological spasticity and aesthetics, and Cabometyx (cabozantinib) for kidney and liver cancer (licensed from Exelixis).

Ipsen has been expanding its rare disease and oncology pipeline through strategic acquisitions. It acquired Clementia in 2019, gaining Palovarotene (Sohonos), the first treatment for fibrodysplasia ossificans progressiva (FOP), an ultra-rare and devastating bone disorder. More recently, Albireo was acquired in 2023 for Bylvay, a rare pediatric liver disease therapy, and Epizyme in 2022 for Tazverik, an EZH2 inhibitor for lymphoma.

While Ipsen historically relied on licensing agreements (e.g., Cabometyx from Exelixis), it has increasingly developed internal R&D. Its innovation in peptide therapeutics and botulinum toxin formulations has allowed it to differentiate itself in niche therapeutic areas. Ipsen has also partnered with Merck KGaA to commercialize PD-1 inhibitor Bavencio in select markets. As a mid-sized biopharma, Ipsen continues to balance internal innovation, targeted acquisitions, and global partnerships to sustain growth.

‍

Bavarian Nordic (Denmark)

Bavarian Nordic, with a market capitalization of $1.9–2.1 billion, specializes in vaccines for infectious diseases and immunotherapies for cancer. The company is best known for its MVA-BN®-based vaccines, a non-replicating vector platform that has enabled safe and effective vaccines.

Bavarian Nordic’s Jynneos/Imvanex vaccine for smallpox and monkeypox became the only FDA- and EMA-approved monkeypox vaccine in 2022, playing a crucial role in global vaccination efforts during the mpox outbreak. The company also markets vaccines for rabies and tick-borne encephalitis, acquired from GSK in 2019.

Its pipeline includes a Phase 3 RSV vaccine for older adults, which met efficacy endpoints in 2023, making it one of the leading candidates in the RSV vaccine race. The company is also developing a COVID-19 booster using MVA-BN technology and previously worked on a cancer immunotherapy candidate (CV301).

Bavarian Nordic has deep ties to government contracts, supplying smallpox vaccine stockpiles for the U.S. and European nations through BARDA and other agencies. It has also partnered with Janssen (J&J) on an Ebola vaccine regimen and continues to play a key role in global biodefense and pandemic preparedness.

‍

Jazz Pharmaceuticals (Ireland)

Jazz Pharmaceuticals, valued at $8 billion, is a global biotech company focused on neurology and oncology. The company is a leader in sleep disorder therapeutics, with Xyrem/Xywav (sodium oxybate-based therapies) dominating the narcolepsy market for years.

Jazz has expanded into oncology and rare diseases through acquisitions. In 2021, it acquired GW Pharmaceuticals for $7.2 billion, bringing Epidiolex, the first FDA-approved cannabis-derived epilepsy treatment, into its portfolio. Other major acquisitions include Celator (Vyxeos, a liposomal chemotherapy for AML) and Immunomedics’ hematology portfolio.

Jazz’s strategy has been aggressive M&A, supported by strong cash flows from its narcolepsy franchise. While headquartered in Dublin, most of its operations are in the U.S., exemplifying a transatlantic biotech model. The company continues to expand its neurology and rare disease footprint, leveraging both internal innovation and external acquisitions to sustain long-term growth.

‍

BenevolentAI (UK)

BenevolentAI, with an estimated market capitalization of $1.5 billion at its 2022 SPAC merger, has since experienced valuation fluctuations, reflecting the challenges of AI-driven biotech investments. The company applies artificial intelligence (AI) to drug discovery, integrating vast biomedical datasets—including genomic, clinical, and molecular data—to identify novel drug targets and optimize therapeutic design.

The company's proprietary Benevolent Platform™ combines machine learning, knowledge graphs, and predictive modeling to uncover hidden relationships in biomedical data. This approach significantly accelerates drug discovery, aiming to cut years off traditional R&D timelines and improve the success rate of clinical candidates. A notable achievement was BenevolentAI’s early identification of Baricitinib as a potential COVID-19 treatment in 2020. The AI-driven insight led to Baricitinib’s emergency use authorization by regulatory agencies, demonstrating the platform’s potential in drug repurposing.

BenevolentAI has built a broad pipeline of around 20 drug candidates across fibrosis, ophthalmology, and neurology. Its high-profile partnership with AstraZeneca, initiated in 2019 and extended in 2021, focuses on target discovery for kidney disease and idiopathic pulmonary fibrosis. Additionally, the company collaborates with academic institutions and smaller biotech firms to advance AI-powered research.

Despite securing significant venture capital funding—including from Temasek and top-tier tech investors—BenevolentAI has faced stock volatility, a common challenge among AI-driven biotech firms. In April 2022, it went public via a SPAC listing on Euronext Amsterdam, securing a valuation of €1.5 billion, making it one of Europe’s largest AI-focused biotech IPOs. However, like many companies in this niche, its valuation has been subject to market corrections and shifting investor sentiment.

BenevolentAI represents the next frontier of biotech, pioneering the integration of AI and data science with drug discovery. While most of its candidates remain in early-stage development, its innovative platform and strategic partnerships highlight AI’s growing role in transforming pharmaceutical R&D.

‍

‍

Exscientia (UK)

Exscientia, with an estimated $1 billion market capitalization in 2023, is a leader in AI-driven small-molecule drug discovery. The company was the first to advance an AI-designed drug molecule into clinical trials, demonstrating the potential of AI to streamline drug design and optimize therapeutic efficacy.

One of Exscientia’s landmark achievements was the development of DSP-1181, an AI-designed compound for obsessive-compulsive disorder (OCD), which entered clinical trials in 2020 in partnership with Sumitomo Dainippon Pharma. The company’s AI-driven approach accelerates drug discovery by reducing the number of compounds needed to find a viable lead, cutting down development time from years to months.

Exscientia has formed major strategic partnerships, including a groundbreaking $5.2 billion collaboration with Sanofi in 2022. Under this agreement, Exscientia applies its AI-driven platform to develop up to 15 oncology and immunology drug candidates, receiving $100 million upfront and the potential for billions in milestone payments. Other key collaborations include Bristol Myers Squibb (BMS), with multiple AI-designed immuno-oncology drugs in development, and Roche, reinforcing Exscientia’s position as a leading AI-powered biotech innovator.

Exscientia’s end-to-end AI drug discovery platform integrates automated target identification, compound optimization, and patient tissue testing, allowing for real-world validation of AI-generated hypotheses. This active learning loop, where experiments continually refine AI predictions, makes Exscientia’s approach particularly compelling.

The company has raised substantial funding to support its expansion. It went public on Nasdaq in October 2021, raising $305 million, following a $525 million private financing round that included backing from top biotech investors. These financial milestones underscore the confidence in Exscientia’s ability to redefine drug discovery.

Alongside BenevolentAI, Exscientia positions Europe at the forefront of AI-driven biotech innovation. Its partnerships with Sanofi, BMS, and Roche validate its approach and emphasize the pharmaceutical industry’s growing reliance on AI. If Exscientia’s AI-designed drugs prove successful in clinical trials, it could mark a transformational shift in drug development, increasing efficiency and reducing costs. By leveraging AI to shorten drug discovery timelines, Exscientia is shaping the future of precision medicine and reinforcing Europe’s role in the global biotech landscape.

‍

Industry Analysis

Key Trends Shaping European Biotech

The European biotech industry is experiencing rapid advancements, fueled by innovation in artificial intelligence, gene therapy, personalized medicine, and new vaccine technologies. These trends are reshaping how therapies are discovered, developed, and delivered, making Europe a competitive force in the global biotech landscape.

AI-Driven Drug Discovery

Artificial intelligence is transforming biotech, particularly in drug discovery. Companies like BenevolentAI and Exscientia are leading the charge, using AI to accelerate target identification, optimize compound selection, and reduce development timelines. AI can analyze vast datasets—ranging from genomic sequences to clinical trial results—to uncover novel drug candidates faster than traditional methods. In 2023, Sanofi signed a $5.2 billion AI drug discovery deal with Exscientia, highlighting big pharma’s confidence in AI-driven R&D. AI-based models can reduce the number of compounds needed to find a lead by over 90%, significantly cutting costs and improving efficiency. Despite being in early stages, AI-designed drugs are already entering human trials, and if proven successful, Europe could emerge as a leader in AI-powered biotech.

‍

Gene Therapy and Genome Editing

Europe has a rich history in gene therapy, from pioneering the first-ever approved therapy Glybera to recent breakthroughs in hemophilia gene therapies. With companies like CRISPR Therapeutics, Freeline, Orchard Therapeutics, and uniQure, Europe remains at the forefront of gene editing innovations. The European Medicines Agency (EMA) has established the PRIME scheme to accelerate promising gene and cell therapies, supporting regulatory approvals and commercialization. However, challenges remain, including high costs, complex manufacturing, and competition from China, which has seen its share of global gene therapy trials rise from 9% in 2017 to 20% in 2022, surpassing Europe’s 17%. To maintain leadership, European biotech must innovate in non-viral vectors, advanced genome editing, and scalable manufacturing while demonstrating durable patient outcomes.

‍

Personalized & Precision Medicine

The shift toward personalized medicine is redefining how diseases are treated. European biotechs are investing heavily in CAR-T and TCR therapies, cancer vaccines, and targeted gene therapies tailored to individual patients. Immunocore’s tebentafusp, a first-in-class TCR therapy for melanoma, exemplifies how personalized approaches are advancing oncology treatment. Companies like Autolus, Adaptimmune, BioNTech, and CureVac are developing neoantigen-based cancer vaccines, which could provide customized treatments based on a patient’s tumor profile. Europe also has a robust diagnostics sector, with companies like Qiagen and BioMérieux providing critical tools for patient stratification. The UK’s Genomic Medicine Service and EU-funded pharmacogenomics projects further support precision medicine by integrating genetic testing into clinical decision-making. As biomarker-driven drug development becomes standard, European biotech is well-positioned to lead in this paradigm shift.

‍

mRNA and Next-Gen Vaccines

The success of mRNA vaccines has spurred a new era in RNA-based therapies, extending beyond infectious diseases to cancer immunotherapy, protein-replacement therapies, and rare genetic disorders. European companies such as BioNTech, CureVac, and Moderna’s European division are driving this trend. In addition to mRNA, Europe is advancing viral vector vaccines and therapeutic cancer vaccines. France’s Transgene and the Netherlands’ ISA Pharmaceuticals are working on neoantigen vaccines tailored to an individual’s immune system. Public-private partnerships, like the EU’s Vaccine Strategy, have channeled billions into vaccine R&D, ensuring continued innovation in pandemic preparedness and emerging infectious diseases. Regulatory agencies have also demonstrated flexibility in fast-tracking innovative vaccine approvals, setting a precedent for future vaccine technologies.

‍

Convergence of Biotech and Digital Health

The fusion of biotech, computational biology, and digital health is accelerating drug development. Computational biology and bioinformatics are enabling in silico trials, reducing reliance on animal testing and speeding up regulatory submissions. Companies like Genenta Science are using machine learning and gene therapy to personalize cancer treatments, while wearable technologies are being integrated into clinical trials to remotely monitor patient responses. The EU’s Horizon Europe grants are supporting interdisciplinary projects that combine biotechnology with AI, cloud computing, and medical devices. This digital transformation is shaping an ecosystem where pharmaceutical companies, AI startups, and biotech firms collaborate to enhance drug discovery and patient care.

‍

Regulatory Landscape and Funding Climate

Regulatory Landscape

The European Medicines Agency (EMA) centrally manages drug approvals across the EU, ensuring access to a market of 500 million people. Europe has been a leader in approving innovative treatments, sometimes ahead of the US. For instance, the EMA approved CAR-T therapy slightly after the FDA but was quicker on gene therapies like Bluebird Bio’s Zynteglo for beta-thalassemia. The EMA also created the PRIME designation, a fast-track system that helps high-potential therapies gain expedited approval. However, regulatory hurdles remain: the country-by-country reimbursement process slows down market access, and Brexit has added complexity as the UK’s MHRA now operates independently from the EMA.

‍

Funding Climate

European biotech funding has improved dramatically over the past decade but still lags behind the US and China. In 2023, European biotechs attracted ~$11.5 billion in venture capital, approximately 7% of global biotech investment, compared to $56.8 billion in the US and $20.6 billion in China. European IPOs have been notable—Oxford Nanopore, Exscientia, and Evotec raised hundreds of millions—but many still opt for Nasdaq listings to access deeper capital pools.

The EU and national governments have stepped up funding efforts. France’s €7 billion innovation fund, Germany’s Zukunftsfonds, and the European Investment Bank (EIB) are supporting biotech ventures. The Horizon Europe program has provided non-dilutive grants for early-stage R&D, helping de-risk projects before venture capital investment. Despite market fluctuations, biotech remains a priority sector for European policymakers, ensuring continued funding for innovation.

‍

Competitive Position vs. Global Players

European biotech competes with the US and China, both of which have larger funding ecosystems. However, Europe excels in scientific research, collaborative networks, and regulatory innovation. Over 33% of the world’s novel biologics originate from European research institutions and biotech firms. Challenges remain, including fragmented reimbursement policies, lower risk appetite from investors, and talent migration to the US. To remain competitive, Europe must continue fostering venture capital investment, regulatory efficiency, and cross-border biotech hubs.

While the US dominates in late-stage biotech funding and China aggressively expands its biotech sector, Europe remains a leader in foundational research and emerging therapeutic areas. By leveraging its strengths in AI, gene therapy, personalized medicine, and vaccine development, European biotech is well-positioned to expand its global influence in the coming decade.

‍

Future Outlook

Growth Predictions for the Next Decade

The outlook for European biotech over the next decade remains optimistic, with strong growth projected in both scientific breakthroughs and market expansion. The global biotech market is expected to grow at a 13–14% compound annual growth rate (CAGR) through 2030, with Europe positioned to maintain or increase its share. Some forecasts predict that European biotech revenues could triple by 2030, driven by new product approvals, expanded investment, and greater adoption of advanced therapies.

‍

Product Approvals and Market Expansion

Many European biotechs have late-stage pipelines that could reach the market by 2030, contributing to substantial revenue growth. Gene therapies, novel antibody drugs, and AI-driven small-molecule therapeutics are expected to dominate approvals. For example, CRISPR-based cures for hemoglobinopathies could be standard-of-care treatments by 2030, significantly reducing healthcare costs while driving biotech revenue. Obesity treatment is also set to be a major driver, with GLP-1 receptor agonists—like those pioneered by Novo Nordisk—expected to fuel a $100 billion market by the decade’s end. Oncology will remain a revenue powerhouse, as niche cancer therapies accumulate to form a major market share.

Despite the extraordinary 35% revenue growth in 2021 driven by COVID vaccines, industry-wide biotech revenue growth of around 10% annually is a more sustainable long-term projection. The shift from pandemic-driven demand to sustained innovation-driven growth will be crucial in determining the sector’s trajectory.

‍

Maturation of the Biotech Ecosystem

By 2030, Europe is expected to have a more mature cohort of biotech firms, with several sustaining market capitalizations above $10 billion. Historically, only a few European biotechs reached such scale independently, but successes like BioNTech and Genmab demonstrate that European firms can achieve sustained growth. This evolution will be fueled by recycled capital, experienced talent, and the emergence of growth-stage investors.

Crossover investors—who traditionally funded US biotech pre-IPOs—are now increasingly active in Europe, allowing companies to stay private longer and expand before IPO or acquisition. Similarly, European venture funds have grown significantly, with several new €500M+ life science funds launched in recent years, ensuring better support for biotech startups as they scale.

‍

Policy and Regulatory Support

European policymakers are increasingly prioritizing biotech as a strategic economic and health security sector. The concept of “health sovereignty”—ensuring Europe produces and controls more of its own medicines—has gained momentum post-pandemic. Initiatives such as the EU’s Pharmaceutical Strategy and HERA (Health Emergency Response Authority) are expected to inject billions into R&D, manufacturing, and stockpiling agreements, similar to BARDA in the US. Tax incentives for R&D (e.g., Belgium, France, and the UK’s R&D tax credits) are also likely to expand, creating a more innovation-friendly investment environment.

According to EuropaBio, the European biotech industry (encompassing healthcare, industrial, and agricultural biotech) could surpass €100 billion in annual revenue by 2030. Within healthcare biotech alone, biologic drug sales from Europe-origin firms are projected to expand significantly, particularly as biosimilars become a larger part of the revenue mix.

‍

Challenges and Opportunities

Despite strong growth prospects, European biotech faces hurdles that must be addressed for sustained success. These challenges also represent opportunities for strategic action.

Funding Volatility and Scaling Up

While European biotech funding has improved, access to late-stage capital remains a challenge. Many companies struggle to secure Phase 3 funding independently, forcing premature licensing or acquisitions by larger pharmaceutical firms. Historically, Europe has seen fewer “biotech-to-pharma” success stories, with many promising firms being acquired before reaching full scale. If more companies stay independent longer (as Genmab and BioNTech have done), Europe’s biotech sector could achieve significantly greater long-term economic impact.

This shift requires stronger public-private funding models, including sovereign investment funds and strategic long-term investors. The opportunity exists for Europe to foster its own large-cap biotech players, similar to how Amgen and Genentech grew in the US.

‍

Regulatory and Market Access Hurdles

Securing regulatory approval is only part of the challenge—biotechs must also navigate reimbursement negotiations in multiple European markets. Companies like Bluebird Bio withdrew their gene therapy from Europe due to pricing difficulties, instead prioritizing the higher-reimbursement US market. This highlights the need for pricing reforms that balance cost control with incentives for innovation.

New pricing models—such as outcome-based payments (where payment is linked to patient success), installment payments for high-cost therapies, and EU-wide joint procurement for ultra-rare disease drugs—could help alleviate market access barriers. Additionally, regulatory harmonization between the EU and the UK’s MHRA could streamline approvals post-Brexit, ensuring smoother European market entry.

‍

Talent and Skills Development

Europe produces world-class scientists, but the lack of experienced biotech leadership remains a bottleneck. Many biotech executives relocate to US hubs (Boston, San Francisco) where opportunities and salaries are higher.

To counter this, Europe must enhance talent mobility within its biotech ecosystem, enabling researchers and entrepreneurs to seamlessly move between innovation hubs (e.g., Paris, Berlin, Basel, and Cambridge, UK). Additionally, offering competitive incentives for biotech founders and executives—such as relocation packages and equity-friendly tax structures—could encourage more biotech leadership to remain in Europe.

‍

Competition and Innovation Speed

China’s biotech sector is growing rapidly and is projected to launch globally competitive drugs by 2030. European biotech must innovate faster to maintain leadership, particularly in AI-driven drug discovery and cell/gene therapy. One challenge is Europe’s fragmented biotech clusters, which operate separately compared to the integrated mega-hubs of Boston and Silicon Valley.

To address this, Europe must strengthen cross-border innovation hubs, such as BioValley (France-Germany-Switzerland), which connects key biotech regions. Encouraging more collaborative EU-funded research programs, akin to COVID vaccine collaborations, could accelerate breakthrough innovations.

‍

Manufacturing and Supply Chain Resilience

The rise of cell therapies, mRNA vaccines, and gene therapies requires advanced biomanufacturing capacity. Historically, Europe has been a leader in biologics manufacturing, with Switzerland and Ireland serving as key hubs. However, many new therapy production facilities are being built in the US and Asia, leading to concerns over supply chain dependence.

Investments in European-based biomanufacturing infrastructure—including mRNA production hubs, viral vector facilities, and CAR-T cell therapy plants—are critical. Governments and private investors are beginning to recognize this, with HERA funding biomanufacturing projects to ensure Europe retains its biotech production capabilities.

‍

Conclusion

Europe’s biotech industry is at a critical inflection point. The sector has demonstrated resilience through economic downturns and the pandemic, proving its ability to deliver world-class innovations. Looking ahead, sustained investment, regulatory modernization, and strategic partnerships will determine whether Europe becomes a global leader in biotech or remains in the shadow of the US and China.

If current trends persist, Europe is well-positioned to solidify its standing as a biopharma powerhouse by 2030. With breakthrough therapies in oncology, metabolic diseases, AI-driven drug discovery, and gene therapy, the next decade will see unprecedented growth and scientific impact. For stakeholders—including investors, policymakers, and biotech leaders—the focus should be on scaling successful companies, streamlining regulatory pathways, and fostering innovation-friendly investment environments.

The stage is set for a new era of European biotech leadership, where scientific excellence translates into tangible patient benefits and economic growth.

‍

‍